Vedomosti: Roszdravnadzor gave Pfizer permission to test a drug for COVID-19 in Russia clinical trials of the effectiveness of the drug against COVID-19. Vedomosti drew attention to the changes in the state register of medicines.
The drug of the American pharmaceutical company is called Paxlovid – it is developed on the basis of a protease inhibitor and ritonavir. The drug is available in capsules, which allows it to be used in outpatient treatment.
Pfizer said the drug can be used to prevent coronavirus and treat patients with severe disease. It reduces the risk of hospitalization or death by 89 percent after contracting COVID-19, the pharmaceutical company noted.
90 Russians over 18 years old who have come into contact with people with COVID-19 symptoms at home will take part in clinical trials. Among them will be residents of the Moscow region, St. Petersburg, Barnaul, Smolensk and other cities.
All over the world, according to Pfizer, seven thousand people are taking part in clinical trials of this drug.
Earlier, the Russian Direct Investment Fund offered Pfizer to use Sputnik Light for a booster vaccination – the third injection. The Foundation said that the increase in the number of people infected with the new COVID-19 strain in the United States and Israel indicates that mRNA vaccines need a heterogeneous booster to enhance and prolong the immune response.